Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMSC-NVs
- Development stage
- Preclinical
- Lead developer
- KAIST
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous (preclinical Studies)
01
Overview
PMSC-NVs are **peptide-functionalized mesenchymal stem cell-derived nanovesicles** engineered to selectively target vascular regions with disturbed blood flow, a characteristic feature of atherosclerosis-prone sites. These nanovesicles are derived from human mesenchymal stem cells (hMSCs) and are functionalized with the peptide GSPREYTSYMPH (PREY) via plasmid modification, improving their ability to home to injured or inflamed endothelium. PMSC-NVs have demonstrated potent **anti-inflammatory** and **pro-endothelial recovery** effects in preclinical (mouse and porcine) models of atherosclerosis, recapitulating the beneficial properties of hMSCs and presenting a novel **theragnostic platform** for atherosclerosis prevention and treatment[1][5]. Mechanistically, PMSC-NVs act through delivery of bioactive molecular cargo (such as proteins, lipids, RNAs) that modulate inflammation and support vascular repair at sites of endothelial dysfunction. The platform is at a preclinical research stage and is not currently approved for use in humans.
- Other names
- PREY-functionalized mesenchymal stem cell nanovesicles
02
Targets
FLNA (Filamin A)
Beyond the preview
Go deeper on PMSC-NVs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMSC-NVs.